Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00698815 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

NIH

Sponsor class

Conditions

Recurrent Non-Small Cell Lung Carcinoma
Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Pemetrexed Disodium
DRUG: Sunitinib Malate

Sponsor

National Cancer Institute (NCI)